-
1 Comment
Lineage Cell Therapeutics, Inc is currently in a long term uptrend where the price is trading 27.2% above its 200 day moving average.
From a valuation standpoint, the stock is 1510.0% more expensive than other stocks from the Other sector with a price to sales ratio of 204.3.
Lineage Cell Therapeutics, Inc's total revenue sank by 71.4% to $355K since the same quarter in the previous year.
Its net income has increased by 145.3% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Lineage Cell Therapeutics, Inc gets an overall score of 2/5.
| Industry | Other |
|---|---|
| Sector | Other |
| ISIN | US53566P1093 |
| CurrencyCode | EUR |
| Exchange | F |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | None |
| PE Ratio | 5.52 |
| Beta | nan |
| Market Cap | 189M |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BT3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
